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Abstract 
Pure red cell aplasia (PRCA) following allogeneic hematopoietic stem cell transplantation 
(HSCT) has been mostly reported in situations involving major ABO incompatibility between 
donor and recipient. Conventional treatments such as plasma exchange, erythropoietin, and 
steroid are often unsatisfactory. Rituximab has been reported to be highly effective for PRCA 
following major ABO-incompatible allogeneic HSCT. A 49-year-old woman with PRCA 
following ABO-matched allogeneic HSCT for acute lymphoblastic leukemia, refractory to 
erythropoietin treatment, received 4 doses of rituximab 375 mg/m
2 weekly. After the 3rd 
dose of rituximab, she exhibited a striking rise in her reticulocyte count with an increase in 
her hemoglobin level. To our knowledge, this is the first case of PRCA following major ABO-
compatible allogeneic HSCT resolving completely after rituximab treatment. 
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Introduction 
Pure red cell anemia (PRCA) is a syndrome characterized by severe normocytic 
anemia, reticulocytopenia, and an absence of erythroblasts from an otherwise normal 
bone marrow [1]. PRCA may appear as a congenital disorder or occur as an acquired 
syndrome. The acquired form of PRCA may present as a primary hematologic disorder 
in the absence of any other diseases, or secondary to various underlying diseases 
including parvovirus B19 infection, large granular lymphocyte (LGL) leukemia and 
other lymphoproliferative disorders, thymoma, autoimmune disease, the use of 
offensive drugs, and allogeneic hematopoietic stem cell transplantation (HSCT) [2]. 
Previously, PRCA following allogeneic HSCT has been reported in patients after ABO-
incompatible allogeneic HSCT. Here, we describe the first case of PRCA, to our 
knowledge, following major ABO-compatible allogeneic HSCT for acute lymphoblastic 
leukemia (ALL) resolving completely after rituximab treatment. 
Case Report 
A 49-year-old woman with ALL underwent HLA-matched related allogeneic HSCT (containing 2.2 × 
106 CD34+ cells/kg) on December 23, 2009. There were no major ABO-mismatch blood types between 
the donor (O+) and the recipient (O+). The duration from transplantation to an absolute neutrophil 
count >0.5 × 109/l and to a platelet count >20 × 109/l was 14 and 17 days. Engraftment was confirmed 
by a bone marrow aspirate and biopsy on day +23. On day +265, she showed elevated aspartate 
transaminase (AST) and alanine transaminase (ALT), and chronic graft-versus-host disease (GVHD) 
was confirmed by a liver biopsy. She was treated with prednisolone and mycophenolate mofetil. Her 
liver enzyme levels then normalized. The prednisolone and mycophenolate mofetil were subsequently 
tapered to 5 and 500 mg on day +452. There was no regular requirement of packed red cell (PRC) 
until then. On day +475, the patient’s hemoglobin level suddenly decreased from 10.3 g/dl to 6.7 g/dl. 
She showed no evidence of GVHD and hemolysis. We started erythropoietin treatment (darbepoetin-α 
120 μg once weekly) on day +492, but there was no improvement in her anemia. A bone marrow 
biopsy was performed on day +545 and revealed a decreased erythroid series without abnormal 
findings of other cell components, showing a consistent finding of PRCA. In addition, we checked for 
parvovirus B19 and cytomegalovirus, and there was no evidence of viral infections. We started 
rituximab 375 mg/m2 once weekly for four weeks starting on day +566. On day +587, hemoglobin and 
reticulocyte began to rise from 6.7 g/dl and 0.4% (12,000/μl) to 9.6 g/dl and 4.44% (150,500/μl) (fig. 
1). There were no adverse reactions to rituximab treatment. Currently (on day +732), the patient has 
no transfusion requirement and her hemoglobin level has remained as high as 13.2 g/dl. 
Discussion 
PRCA following allogeneic HSCT has been mostly reported in situations involving 
major ABO incompatibility between donor and recipient [3, 4], with the exception of 
one case following major ABO-matched allogeneic HSCT [5]. PRCA following ABO-
incompatible allogeneic HSCT is associated with an interaction of recipient anti-A or 
anti-B isoagglutinins with donor erythroid precursors expressing A and/or B antigens 
[6]. Spontaneous remission has been noted but treatments such as plasma exchange, 
donor-derived leukocyte infusion, erythropoietin, and steroids may be necessary to 
avoid RBC transfusion and to decrease the risk of hemochromatosis [7–11]. 
The mechanism of PRCA following major ABO-matched allogeneic HSCT is unclear. 
In the case report by Roychowdhury and Linker [5], it is speculated that immune- 
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mediated etiology such as the adoptive transfer of autoimmunity or antibodies to 
erythroid progenitors resulted in PRCA. In addition, non-ABO antigens may be involved 
in PRCA following allogeneic HSCT. 
Our case was analyzed following allogeneic HSCT between a major ABO-matched 
donor-recipient pair. We found no evidence of infections, hemolysis, and causative 
medications. The treatment with erythropoietin showed no improvement. Rituximab is 
a humanized, murine, monoclonal antibody directed against the CD20 antigen, 
expressed on pre-B lymphocytes and on mature B lymphocytes [12]. Rituximab has 
been showed to be highly effective for immune-mediated PRCA, autoimmune 
cytopenias, and PRCA following ABO-incompatible allogeneic HSCT [13–15]. We started 
rituximab 375 mg/m2 once weekly for four weeks. After the third anti-CD20 
monoclonal antibody infusion, the patient exhibited a striking rise in her reticulocyte 
count, and then had a progressive increase in her hemoglobin level. 
To our knowledge, this is the first report of rituximab use for the treatment of PRCA 
following major ABO-matched allogeneic HSCT. Rituximab seems to be a promising 
therapeutic option for patients with PRCA following ABO-matched and ABO-
mismatched allogeneic HSCT. 
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Fig. 1. Clinical course and changes in hemoglobin (black diamonds) and reticulocyte counts (open 
circles). The arrows show the four seperate infusions of the anti-CD20 monoclonal antibody. The 
black circles represent erythropoietin injections and the black bars represent packed red cell 
transfusion. 
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